ArticleJournal of the American Heart Association2025
Hemorrhagic Stroke in Atrial Fibrillation: Trends in Incidence, Case Fatality, and Prior Oral Anticoagulation.
Article in Journal of the American Heart Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Systematic review and meta-analysis of stroke blood biomarker data highlights need for more translational research methods.Nature communications · 2026Pooled it
- NovelBiomedicines · 2026Article
- Rare TruncatingGenes · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDespite increased atrial fibrillation (AF) and oral anticoagulation (OAC) use among patients with intracerebral hemorrhage, trends in hemorrhagic stroke (HS) incidence in AF remain unclear. We examined recent epidemiological trends, considering advances in stroke prevention and an aging population. METHODS AND
resultsA Finnish nationwide study using linked administrative registries followed 168 121 patients with incident AF (2009-2017) until the first-ever intracerebral or subarachnoid hemorrhage, death, or study end (November 2018). HS incidence rates, the proportion of fatal cases (case fatality rate %), and anticoagulant purchases within 90 days before HS were analyzed. Temporal trends were assessed using logistic and Poisson regression. A total of 1890 patients with AF (53% women, median age 80.2) experienced their first-ever HS. The average annual incidence rate was 2.82/1000 PY (95% CI, 2.72-2.92), remaining stable over 10 years (range 2.62-3.22). Age-standardized incidence rates were 2.65 (2.48-2.82) for women and 2.94 (2.70-3.15) for men. The annual case fatality rate averaged 46.5% (43.9%-49.1%) without notable temporal or sex differences. Older age was associated with higher incidence rates and case fatality rate, with an increasing proportion of patients over 84. Prior OAC use increased: in 2009, 67% were not on OACs but by 2018, one third used warfarin, one third direct OACs, and only one third were without any OAC. No association was found between anticoagulation and HS case fatality.
conclusionsAmong the population with incident AF, we observed a stable first-ever HS incidence rate and short-term case fatality over the past decade despite a marked increase in prior oral anticoagulation use and aging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.